Pfizer's Rituxan Biosimilar Gets Thumbs-Up from FDA for Multiple Indications - BioSpace

Pfizer's Rituxan Biosimilar Gets Thumbs-Up from FDA for Multiple Indications  BioSpace

It is approved for adults with non-Hodgkin's lymphoma, chronic lymphocytic leukemia, granulomatosis with polyangiitis and microscopic polyangiitis.



Comments

Popular posts from this blog

Fibromyalgia — Latest Stories — Pain News Network

Chronic Lyme arthritis: A mystery solved?

Epstein-Barr virus and autoimmune diseases